Glucocorticoids and intravenous immunoglobulins are widely accepted and recommended in guidelines for the treatment in pregnancy. On the other hand, the safety profile of the other options during pregnancy is not well known. Since ITP affects not only pregnant women but also neonates, the effective communication among hematologists, obstetricians, and pediatricians should be established for efficient management.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Gill KK, Kelton JG. Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol. 2000;37(3):275–89.CrossRefPubMedGoogle Scholar
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMedGoogle Scholar
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.CrossRefPubMedGoogle Scholar
British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.CrossRefGoogle Scholar
Miyakawa Y. [Consensus report on the management of immune thrombocytopenia in pregnancy]. Rinsho Ketsueki 2015; 56(10):2086–91.Google Scholar
Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 2002;75(4):426–33.CrossRefPubMedGoogle Scholar